Ensayo clínico

Phase 1/2a Study of ANPD001 in Parkinson Disease

NCT: NCT06344026 · ENROLLING_BY_INVITATION

ID NCTNCT06344026

EstadoENROLLING_BY_INVITATION

Fecha de inicio2024-01-23

Finalización2030-04-30

SponsorAspen Neuroscience (INDUSTRY)

First posted2024-04-03

Last updated2026-05-14

Resumen breve

This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells.

Fuente oficial

Ver en ClinicalTrials.gov →

Datos obtenidos de la API de ClinicalTrials.gov. Para conocer el estado más reciente, consulte el registro oficial.